Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Drug development in the field of neurological diseases

15.11.2001


The Idea

Our company has successfully been focusing on drug development in the field of neurological diseases. We give pharmaceutical companies the exceptional opportunity to cooperate in these projects with defined exclusive rights to commercialize the respective products.

The cooperation partners

  • Chemical, pharmaceutical and biotechnological companies

  • Venture capital firms, financing agencies, independent consultants, patent lawyers

  • Biomedical research institutions (medical centers, uni-versities, foundations)

The technology

We successfully apply protein-biochip based technology. Genomic analyses of protein interactions are used to identify new pharmaceutical targets or endogenous drugs to fill our product-pipeline.

The candidates

AIDS associated myelopathies, orphan drug status I.

  • Status quo: Phase II completed, time to market probably in 2002, FDA admission expected shortly
  • Total market volume: (AIDS associated myelopathies): In the US about € 30 million a year, with admission in Europe the market potential increases to about € 70 million a year
  • Further information: About 40 percent of all AIDS patients develop neurological striking myelopathies as side effect of their immune deficiency syndrome. The HIV virus attacks the central nervous system. Because the protease inhibitors cannot pass through the blood-brain barrier of the central nervous system, the HIV virus is resistant to the protease inhibitors being the common medication of AIDS patients. The blood- brain barrier, however, is permeable to ODS I, because it is an endogenous substance, whose level of cerebrospinal fluid especially of AIDS patients with myelopathy is extremely lowered. ODS I is especially suited for comedication with protease-inhibitors to increase their effect.


Parkinson’s disease associated depression, orphan drug status II.

  • Status quo: Phase I successful, phase II initiated, time to market probably in 2003
  • Total market volume:(Parkinson’s disease associated Depression): In the US about € 100 million a year, with admission in Europe the market potential increases to about € 230 million a year
  • Further information: ODS II is a substance reducing depressions of Parkinson patients. Depressions are a frequent side effect of the common treatment with L-DOPA. About 20 to 25 percent of the 500,000 to 1,000,000 Parkinson patients suffer from these side effects. ODS II, an endogenous substance, showed a similar efficiency in clinical studies of phase I, but better toleration as conventional antidepressants.


Stroke and cardiac infarcts

  • Status quo: Preclinical studies
  • Total market volume:€ 50 billion a year world-wide
  • Further information:We own the patent for a new target to treat reperfusion damages of patients with stroke syndrome. Animal experiments have shown that a newly discovered endo-genous factor of brain tissue has an effect on this target and therefore dramatically increases the survival of nerve cells after oxygen deficiency.


Epilepsy

  • Status quo Functional characterization
  • Total market volume:€ 1.4 billion a year world-wide
  • Further information:We have identified a completely new class of channel proteins, being directly involved in the regulation of the membrane-resting potential.


Multiple sclerosis

  • Status quo Preclinical studie
  • Total market volume:€ 670 million a year world-wide
  • Further information An endogenous factor of cerebrospinal fluid from multiple sclerosis patients blocks sodium channels of nerve fibres in a self-defence mechanism. In animal experiments the pro-tective effect on multiple sclerosis has been investigated.

| Genopia Biomedical GmbH
Weitere Informationen:
http://www.genopia.de

Weitere Berichte zu: Aids Drug ODS Parkinson

Weitere Nachrichten aus der Kategorie Biowissenschaften Chemie:

nachricht Kieselalge in der Antarktis liest je nach Umweltbedingungen verschiedene Varianten seiner Gene ab
17.01.2017 | Stiftung Zoologisches Forschungsmuseum Alexander Koenig, Leibniz-Institut für Biodiversität der Tiere

nachricht Proteinforschung: Der Computer als Mikroskop
16.01.2017 | Ruhr-Universität Bochum

Alle Nachrichten aus der Kategorie: Biowissenschaften Chemie >>>

Die aktuellsten Pressemeldungen zum Suchbegriff Innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Erforschung von Elementarteilchen in Materialien

Laseranregung von Semimetallen ermöglicht die Erzeugung neuartiger Quasiteilchen in Festkörpersystemen sowie ultraschnelle Schaltung zwischen verschiedenen Zuständen.

Die Untersuchung der Eigenschaften fundamentaler Teilchen in Festkörpersystemen ist ein vielversprechender Ansatz für die Quantenfeldtheorie. Quasiteilchen...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Mit solaren Gebäudehüllen Architektur gestalten

Solarthermie ist in der breiten Öffentlichkeit derzeit durch dunkelblaue, rechteckige Kollektoren auf Hausdächern besetzt. Für ästhetisch hochwertige Architektur werden Technologien benötigt, die dem Architekten mehr Gestaltungsspielraum für Niedrigst- und Plusenergiegebäude geben. Im Projekt »ArKol« entwickeln Forscher des Fraunhofer ISE gemeinsam mit Partnern aktuell zwei Fassadenkollektoren für solare Wärmeerzeugung, die ein hohes Maß an Designflexibilität erlauben: einen Streifenkollektor für opake sowie eine solarthermische Jalousie für transparente Fassadenanteile. Der aktuelle Stand der beiden Entwicklungen wird auf der BAU 2017 vorgestellt.

Im Projekt »ArKol – Entwicklung von architektonisch hoch integrierten Fassadekollektoren mit Heat Pipes« entwickelt das Fraunhofer ISE gemeinsam mit Partnern...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Bundesweiter Astronomietag am 25. März 2017

17.01.2017 | Veranstaltungen

Über intelligente IT-Systeme und große Datenberge

17.01.2017 | Veranstaltungen

Aquakulturen und Fangquoten – was hilft gegen Überfischung?

16.01.2017 | Veranstaltungen

 
VideoLinks
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Bundesweiter Astronomietag am 25. März 2017

17.01.2017 | Veranstaltungsnachrichten

Intelligente Haustechnik hört auf „LISTEN“

17.01.2017 | Architektur Bauwesen

Satellitengestützte Lasermesstechnik gegen den Klimawandel

17.01.2017 | Maschinenbau